<DOC>
	<DOCNO>NCT01546428</DOCNO>
	<brief_summary>INC280 administer Japanese patient advanced soid tumor whose disease progress despite standard therapy standard therapy exist . The trial ass safety tolerability determine maximum tolerate dose ( MTD ) INC280</brief_summary>
	<brief_title>A Phase I Study INC280 Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor refractory currently available therapy effective treatment available . Eastern Cooperative Oncology Group ( ECOG ) Performance Status â‰¤ 2 Good organ ( hepatic , kidney , BM ) function screening/baseline visit . Exclusion criterion : Symptomatic CNS metastasis neurologically unstable require increase dos steroid control CNS disease . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption INC280 . Undergone bone marrow solid organ transplant . Women pregnant breast feeding . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>c-MET</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>